Nasus Pharma Ltd (NSRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2025 | |
| Assets | |
| Current Assets | |
| Cash & Cash Equivalents | 232 |
| TOTAL | $291 |
| Non-Current Assets | |
| Other Non-Current Assets | 348 |
| TOTAL | $348 |
| Total Assets | $639 |
| Liabilities | |
| Current Liabilities | |
| Short Term Debt | 2,563 |
| Accounts payable and accrued liabilities | 664 |
| Accrued Expenses | 1,179 |
| TOTAL | $4,953 |
| Non-Current Liabilities | |
| TOTAL | $N/A |
| Total Liabilities | $4,953 |
| Shareholders' Equity | |
| Common Shares | 20 |
| Retained earnings | -13,916 |
| TOTAL | $-4,314 |
| Total Liabilities And Equity | $639 |